Hydrix (ASX:HYD) said that Gyder Surgical, a client and investee, has received US Food and Drug Administration (FDA) clearance to sell its Gyder Hip System in the United States, according to a Monday filing with the Australian bourse.
The system, which is a pin-less and image-less navigation solution for hip surgery, has also been approved by Australia's Therapeutic Goods Administration, the filing said.
The FDA approval triggers an AU$0.3 million equity payment to Hydrix Ventures, increasing its investment in Gyder to AU$2.65 million, the filing added.
Shares of the company rose 67% at market close, and earlier hit a 52-week high.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.